menu
    • menu
    [{"orgOrder":0,"company":"Olpha","sponsor":"Not Applicable","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2021","type":"Agreement","leadProduct":"Furazidin","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Olpha","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Olpha \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Olpha \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Furazidin

    Menu

    Furazidin

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    MARKET PLACE

    ANALYTICAL

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Olpha

                            Latvia
                            BMWS24
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothOlpha, a JSC AB City subsidiary, is a leading Baltic firm with 50 years of experience in medicines & chemical pharmaceuticals.

                            Lead Product(s) : Furazidin

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            JSC Olainfarm & Adalvo to Launch a New Urology Product in 17 Countries In 2022-2023

                            Details : In partnership Olainfarm will manage Furagins (Furaginum) regulatory affairs, distribution and promotion in Latvia, Russia, Kazakhstan, Belarus, Ukraine, and other countries and Adalvo will be responsible for development, manufacturing and will support m...

                            Brand Name : Furagins

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            June 16, 2021

                            Lead Product(s) : Furazidin

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            Olpha

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth